Source: Medical Daily
By: Weiss, Jonathan
Coridon, an Australian biotechnology company, will commence early-stage, Phase I human trials of its herpes simplex 2 (HSV-2) vaccine. The HSV-2 vaccine would be used as a preventive vaccine and a therapeutic vaccine for those already infected with genital herpes. Another HSV-2 vaccine has been developed by Genocea, which is pursuing clinical trials. GlaxoSmithKline’s vaccine, however, failed in late-stage clinical trials.